Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Quyen La

Optometrist Huntington Beach, CA Doctor of Optometry

NPI 1750466777 CMS profile 641063

7251 Warner Ave Ste H, Huntington Beach, CA 92647

Open in the dashboard

General payments

$9,011

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Quyen La of Huntington Beach, CA is reported in the CMS Open Payments database as having received $9,011 across 155 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,290 27
2024 General $1,983 23
2023 General $1,042 25
2022 General $1,619 26
2021 General $827 19
2020 General $423 13
2019 General $1,828 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Quyen La
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Quyen La were reported at $1,290. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Quyen La Optometrist median Middle half National median
2019 $1,828 $159 $67–$371 $163
2020 $423 $72 $29–$165 $114
2021 $827 $125 $46–$292 $132
2022 $1,619 $162 $66–$374 $149
2023 $1,042 $177 $72–$406 $160
2024 $1,983 $188 $77–$427 $164
2025 $1,290 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $4,679 96 payments
  2. Alcon Vision LLC $1,399 14 payments
  3. Sight Sciences, Inc. $825 6 payments
  4. Sun Pharmaceutical Industries Inc. $757 17 payments
  5. Bausch & Lomb Americas Inc. $270 3 payments
  6. Dompe US, Inc. $147 2 payments
  7. Kala Pharmaceuticals, Inc. $146 2 payments
  8. Oyster Point Pharma, Inc. $144 2 payments
  9. Shire North American Group Inc $143 3 payments
  10. Allergan Inc. $128 2 payments
  11. Other $372 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,217 151 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 2 payments
  3. Travel and Lodging $794 2 payments
Products named General payments · program years 2019–2025
  1. Clariti Contact Lens $2,661 67 payments
  2. MiSight Contact Lens $1,391 13 payments
  3. DAILIES $1,157 9 payments
  4. Cequa $757 17 payments
  5. OMNI(R) SURGICAL SYSTEM (US) $525 3 payments
  6. MyDay Contact Lens $445 11 payments
  7. MIEBO $270 3 payments
  8. XIIDRA $250 2 payments
  9. DAILIES TOTAL1 $210 4 payments
  10. Multiple Brands Contact Lens $182 5 payments
  11. Other $1,487 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Optometry: 120

Drug cost

$6,713

Median for Optometry: $8,864

Branded share of claims

0%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cyclosporine Generic 11 $6,713

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Syfovre
  • Apellis Pharmaceuticals, Inc. $120
$120 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record